AstraZeneca signed an agreement with the Carlos Slim Foundation, a Mexican non-profit organization, to contribute to the production in Argentina and Mexico and distribution without economic benefit in Latin America, of the potential COVID-19 vaccine, AZD1222, during the pandemic.
This agreement will initially provide 150 million doses in the region, excluding Brazil, which will be covered by AstraZeneca’s agreement with the Brazilian Government announced last June. Shipments are expected to begin in the first half of 2021, should clinical trials be successful.
Sylvia Varela, President and CEO of AstraZeneca, Mexico, stated: “For us, the work that AstraZeneca does on the science front and within the industry to help save lives and mitigate the devastating humanitarian consequences is a source of great pride. , social and economic that this global pandemic has had. And, in particular, it fills us with great satisfaction to be part of an alliance with partners in Latin America where our sole objective is to provide rapid access to potential vaccine in Mexico and throughout the Latin American region ”.
The Carlos Slim Foundation said: “We are concerned about collaborating in combating this unprecedented pandemic that has a great impact on health, the economy and employment, with consequences for people and their families. We regret the loss of many lives, as well as the impact on the global economy and employment.
Based on the research of the University of Oxford and AstraZeneca, a potential vaccine is in development that is in phase 3 with encouraging expectations, consequently we join the effort for its production in Mexico and Argentina in order to start the supply to Latin America. If its efficacy and safety are proven and approved by the health authorities, it would contribute decisively to avoid further loss of life, and would allow a return to normalcy “